Last reviewed · How we verify
Lianhua Qingwen capsules
Lianhua Qingwen capsules, marketed by Qilu Hospital of Shandong University, hold a significant position in the respiratory health segment. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Lianhua Qingwen capsules |
|---|---|
| Sponsor | Qilu Hospital of Shandong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19 (NA)
- Lianhua Qingwen for the Rehabilitation of Patient With Coronavirus Infection (PHASE4)
- A Phase I Pharmacokinetics Study for KT07 Capsule (PHASE1)
- A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19 (PHASE3)
- A Clinical Trial of KT07 Capsule in the U.S.A (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |